相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
Camille C. B. Kockerols et al.
HAEMATOLOGICA (2023)
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia- What to look for when treatment-free remission is not an option
Jeffrey H. Lipton et al.
BLOOD REVIEWS (2022)
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1
Delphine Rea et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)
An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors
Valentin Garcia-Gutierrez et al.
EXPERT REVIEW OF HEMATOLOGY (2022)
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Management of TKI-resistant chronic phase CML
Timothy P. Hughes et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
Valentin Garcia-Gutierrez et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
A. Luna et al.
ANNALS OF HEMATOLOGY (2022)
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Valentin Garcia-Gutierrez et al.
BLOOD CANCER JOURNAL (2021)
Future Directions in Chronic Phase CML Treatment
Nathalie Javidi-Sharifi et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
Delphine Rea et al.
BLOOD (2021)
Asciminib: an investigational agent for the treatment of chronic myeloid leukemia
Massimo Breccia et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase
Paul W. Manley et al.
LEUKEMIA RESEARCH (2020)
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
Valentin Garcia-Gutierrez et al.
FRONTIERS IN ONCOLOGY (2019)
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
Christopher A. Eide et al.
CANCER CELL (2019)
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
Federica Loscocco et al.
FRONTIERS IN ONCOLOGY (2019)
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
T. P. Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes et al.
BLOOD (2018)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A. Hochhaus et al.
LEUKEMIA (2016)
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
J. L. Steegmann et al.
LEUKEMIA (2016)
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
Tim H. Bruemmendorf et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Drug discovery and the human kinome: Recent trends
Richard Eglen et al.
PHARMACOLOGY & THERAPEUTICS (2011)
Tyrosine kinase inhibitors in cancer therapy
S Madhusudan et al.
CLINICAL BIOCHEMISTRY (2004)